# DESTINY-B12 (NCT04739761)

> A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04739761
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer
- Interventions: Trastuzumab Deruxtecan
- Enrollment: 506
- Primary outcome: Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)
- Primary outcome: Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)

## Commentary we found

- YouTube: 67
- Podcasts: 35
- X threads: 23
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-b12-nct04739761

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04739761", "email": "<work email>"}; the inbox owner confirms by the emailed link.